Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Celldex Therapeutics (NASDAQ: CLDX ) were getting rejected by investors today, falling as much as 17% after reporting earnings this morning.
So what: Celldex reported a $0.27 per share loss on revenue of $3.6 million. Earnings missed estimates, while sales beat them, but that is mostly irrelevant since Celldex is a development-stage biopharmaceutical company. Overall, the report looks strong with the company showing positive data from a phase 2b study of CDX-011 in metastatic breast cancer, as well as encouraging survival data from phase 2 studies of rindopepimut. The company's cash position also improved over 2012, adding $30 million through additional financing, which management said will "support operations and clinical development through 2015."
Now what: Today's drop could simply be a secular pullback as Celldex shares have gained 300% since October 2011 -- and nearly 50% this year alone. With no major immediate breakthroughs on the way, shares seemed due to cool off a bit. Investors may also be reacting to recent share dilution, which was needed to fund R&D. In the first two months of the year, Celldex sold 16 million more shares, diluting investors by 25%. After a volatile opening today, shares have climbed and the stock was down just 5% by midday.
While you can certainly make huge gains in biotech companies like Celldex, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
- Add Celldex Therapeutics to My Watchlist.